Officinae Bio
Private Company
Funding information not available
Overview
Officinae Bio is a Milan-based biotech service company that provides AI-driven mRNA design and optimization services to accelerate therapeutic development. Its core technology is the Mercurius platform, a proprietary AI workflow that models complex biological dependencies to optimize UTRs, polyA tails, and regulatory elements for improved protein expression and tissue targeting. The company offers tiered service bundles (RNAExpress, HITSmart, LEADvantage) tailored to different development stages, from discovery to preclinical. As part of the Maravai LifeSciences ecosystem, it provides clients with a pathway to GMP manufacturing and commercial production.
Technology Platform
Mercurius AI Platform: A proprietary machine learning workflow that uses Bayesian networks and a knowledge graph to model biological dependencies for optimizing mRNA sequence design (UTRs, polyA tails, capping, modifications) to enhance translation, tissue specificity, and stability.
Opportunities
Risk Factors
Competitive Landscape
Officinae Bio competes with other AI-driven drug design companies (e.g., Absci, Recursion) that may offer mRNA services, traditional life sciences CROs providing gene synthesis and optimization, and in-house bioinformatics teams at large biopharma firms. Its differentiation lies in its specialized focus on mRNA component optimization and its seamless connection to manufacturing via Maravai.